Monitor the company's ability to secure regulatory approvals for Orion and stroke recovery systems, and track its cash burn rate post-IPO to assess sustainability without additional funding.
Executive Summary
Cortigent, Inc. is a pre-revenue medical device company developing brain implant systems for artificial vision (Orion) and stroke recovery. It has no revenue, incurred net losses of $3.1 million in 2025, and relies on its parent Vivani for funding. The company plans to use IPO proceeds to fund clinical trials and repay Vivani, but faces significant risks including the need for substantial future capital and uncertainty of regulatory approval.
Key Financial Metrics
Key Facts
- Pre-revenue company with no commercial products
- Incurred net losses of $3.1 million in 2025 and $2.2 million in 2024
- Relies on parent company Vivani for operational funding
- Plans to use IPO proceeds to fund Orion research and repay Vivani
- Orion and stroke recovery systems are investigational devices requiring FDA approval
- Has no commercial revenues and any negative outcomes could require substantial additional funding
Financial Impact
No revenue, $3.1 million net loss in 2025, $13.45 million estimated net proceeds from IPO
Risk Factors
- Requires substantial additional capital to fund operations
- No assurance that clinical trials will demonstrate safety and efficacy
- Dependence on parent company Vivani for funding
- No commercial revenues and history of operating losses
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001753926-26-000480 |
| Document: g085456_ex23-2.htm | 0001753926-26-000480 |
| Document: 0001753926-26-000480-index-headers.html | 0001753926-26-000480 |
| Document: 0001753926-26-000480-index.html | 0001753926-26-000480 |
| Document: 0001753926-26-000480.txt | 0001753926-26-000480 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Mar 17, 2026 32w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 3, 2026 34w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers